Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight ...

People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s Wegovy.

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over ...